Komorbidität depressiver Störungen – Teil I

B. J. Connemann; J. Kassubek

doi:10.1055/s-0038-1626187

Nervenheilkunde, Inhaltsverzeichnis

Nervenheilkunde 2004; 23(01): 5-12
DOI: 10.1055/s-0038-1626187

Original- und Übersichtsarbeiten - Original and Review Articles

Schattauer GmbH

Komorbidität depressiver Störungen – Teil I

Die Rolle von Achse-Iund Achse-II-StörungenComorbidity of depressive disorderspart I: role of axis I and II disorders

Authors

B. J. Connemann

¹Psychiatrische Universitätsklinik Ulm, Abteilung Psychiatrie III
J. Kassubek

²Neurologische Klinik der Universität Ulm

Abstract

Zusammenfassung

Epidemiologische Studien berichten hohe Prävalenzen depressiver Störungen. Nur selten treten Depressionen jedoch isoliert auf. Im ersten Teil dieser einführenden Übersicht werden besonders häufige und relevante komorbide Störungen der Achsen I und II der multiaxialen Klassifikation psychischer Störungen nach DSM-IV dargestellt, im Einzelnen Substanzmissbrauch und -abhängigkeiten, Angststörungen und Persönlichkeitsstörungen. Konsequenzen für das klinische Bild, die Therapie und die Prognose werden diskutiert und Probleme der Klassifikation und des Komorbiditätsbegriffes erörtert.

Summary

Epidemiological studies consistently report high frequencies of depressive disorders. In part I of this introductory review, the comorbidity of depressive disorders and relevant DSM-IV axis I and II disorders is presented, particularly with regard to substance-related disorders, anxiety disorders, and personality disorders. Effects on clinical presentation, treatment options, and prognosis as well as problems of the classificatory system, and of the comorbidity principle, respectively, are discussed.

Schlüsselwörter

Angststörungen - Depression - Persönlichkeitsstörungen - Substanzmissbrauch - Substanzabhängigkeit

Keywords

Anxiety disorders - major depressive disorder - personality disorders - substance-related disorders

Volltext

Referenzen

Literatur
1 Abram KM, Teplin LA, McClelland GM. Comorbidity of severe psychiatric disorders and substance use disorders among women in jail. Am J Psychiatry 2003; 160 (05) 1007-10.
2 Alpert JE, Uebelacker LA, McLean NE, Nierenberg AA, Pava JA, Worthington 3rd JJ, Tedlow JR, Rosenbaum JF, Fava M. Social phobia, avoidant personality disorder and atypical depression: co-occurrence and clinical implications. Psychol Med 1997; 27 (03) 627-33.
3 Andrews G, Henderson S, Hall W. Prevalence, comorbidity, disability and service utilisation. Overview of the Australian National Mental Health Survey. Br J Psychiatry 2001; 178: 145-53 Erratum in: Br J Psychiatry 2001; 179 561 2.
4 Anthenelli RM, Schuckit MA. Affective and anxiety disorders and alcohol and drug dependence: diagnosis and treatment. J Addict Dis 1993; 12 (03) 73-87.
5 Araya R, Rojas G, Fritsch R, Acuna J, Lewis G. Common mental disorders in Santiago, Chile: prevalence and socio-demographic correlates. Br J Psychiatry 2001; 178: 228-33.
6 Bland RC, Orn H, Newman SC. Lifetime prevalence of psychiatric disorders in Edmonton. Acta Psychiatr Scand Suppl 1988; 338: 24-32.
7 Blazer DG, Kessler RC, McGonagle KA, Swartz MS. The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am J Psychiatry 1994; 151 (07) 979-86.
8 Blondal T, Gudmundsson LJ, Tomasson K, Jonsdottir D, Hilmarsdottir H, Kristjansson F, Nilsson F, Bjornsdottir US. The effects of fluoxetine combined with nicotine inhalers in smoking cessation – a randomized trial. Addiction 1999; 94 (07) 1007-15.
9 Breslau N, Davis GC. Further evidence on the doubtful validity of generalized anxiety disorder. Psychiatry Res 1985; 16 (02) 177-9.
10 Canino GJ, Bird HR, Shrout PE, Rubio-Stipec M, Bravo M, Martinez R, Sesman M, Guevara LM. The prevalence of specific psychiatric disorders in Puerto Rico. Arch Gen Psychiatry 1987; 44 (08) 727-35.
11 Carroll KM, Rounsaville BJ, Keller DS. Relapse prevention strategies for the treatment of cocaine abuse. Am J Drug Alcohol Abuse 1991; 17 (03) 249-65.
12 Charney DA, Paraherakis AM, Gill KJ. Integrated treatment of comorbid depression and substance use disorders. J Clin Psychiatry 2001; 62 (09) 672-7.
13 Compton 3rd WM, Cottler LB, Jacobs JL, BenAbdallah A, Spitznagel EL. The role of psychiatric disorders in predicting drug dependence treatment outcomes. Am J Psychiatry 2003; 160 (05) 890-5.
14 Connemann BJ, Kassubek J. Childhood brain tumors and depressive disorders. N Engl J Med 2003; 349 (19) 1868-9.
15 Corbitt EM, Malone KM, Haas GL, Mann JJ. Suicidal behavior in patients with major depression and comorbid personality disorders. J Affect Disord 1996; 20; 39 (01) 61-72.
16 Cornelius JR, Salloum IM, Haskett RF, Ehler JG, Jarrett PJ, Thase ME, Perel JM. Fluoxetine versus placebo for the marijuana use of depressed alcoholics. Addict Behav 1999; 24 (01) 111-4.
17 Cornelius JR, Salloum IM, Thase ME, Haskett RF, Daley DC, Jones-Barlock A, Upsher C, Perel JM. Fluoxetine versus placebo in depressed alcoholic cocaine abusers. Psychopharmacol Bull 1998; 34 (01) 117-21.
18 Corruble E, Ginestet D, Guelfi JD. Comorbidity of personality disorders and unipolar major depression: a review. J Affect Disord 1996; 37 (2-3); 157-70.
19 Dackis CA, Gold MS. Addictiveness of central stimulants. Adv Alcohol Subst Abuse 1990; 09 (2-3); 9-26.
20 Dackis CA, O’Brien CP. Cocaine dependence: a disease of the brain’s reward centers. J Subst Abuse Treat 2001; 21 (03) 111-7.
21 Daley SE, Hammen C, Burge D, Davila J, Paley B, Lindberg N, Herzberg DS. Depression and Axis II symptomatology in an adolescent community sample: concurrent and longitudinal associations. J Personal Disord 1999; 13 (01) 47-59.
22 de Graaf R, Bijl RV, Smit F, Vollebergh WA, Spijker J. Risk factors for 12-month comorbidity of mood, anxiety, and substance use disorders: findings from the Netherlands Mental Health Survey and Incidence Study. Am J Psychiatry 2002; 159 (04) 620-9.
23 Eaton WW, Anthony JC, Gallo J, Cai G, Tien A, Romanoski A, Lyketsos C, Chen LS. Natural history of Diagnostic Interview Schedule/DSMIV major depression. The Baltimore Epidemiologic Catchment Area follow-up. Arch Gen Psychiatry 1997; 54 (11) 993-9.
24 Evans K, Sullivan J. Dual diagnosis: Counselling the mentally ill substance abuser. New York: The Guilford Press; 1990
25 Extein IL, Gold MS. Hypothesized neurochemical models for psychiatric syndromes in alcohol and drug dependence. J Addict Dis 1993; 12 (03) 29-43.
26 Farrell M, Howes S, Bebbington P, Brugha T, Jenkins R, Lewis G, Marsden J, Taylor C, Meltzer H. Nicotine, alcohol and drug dependence and psychiatric comorbidity. Results of a national household survey. Br J Psychiatry 2001; 179: 432-7.
27 Fava M, Farabaugh AH, Sickinger AH, Wright E, Alpert JE, Sonawalla S, Nierenberg AA, Worthington 3rd JJ. Personality disorders and depression. Psychol Med 2002; 32 (06) 1049-57.
28 Ferro T, Klein DN, Schwartz JE, Kasch KL, Leader JB. 30-month stability of personality disorder diagnoses in depressed outpatients. Am J Psychiatry 1998; 155 (05) 653-9.
29 Frances A, Pincus HA, Widiger TA, Davis WW, First MB. DSM-IV: work in progress. Am J Psychiatry 1990; 147 (11) 1439-48.
30 Fu Q, Heath AC, Bucholz KK, Nelson E, Goldberg J, Lyons MJ, True WR, Jacob T, Tsuang MT, Eisen SA. Shared genetic risk of major depression, alcohol dependence, and marijuana dependence: contribution of antisocial personality disorder in men. Arch Gen Psychiatry 2002; 59 (12) 1125-32.
31 Gerra G, Zaimovic A, Zambelli U, Delsignore R, Baroni MC, Laviola G, Macchia T, Brambilla F. Neuroendocrine correlates of depression in abstinent heroin-dependent subjects. Psychiatry Res 2000; 96 (03) 221-34.
32 Gorman JM. Comorbid depression and anxiety spectrum disorders. Depress Anxiety 1996-97; 04 (04) 160-8.
33 Hall SM, Humfleet GL, Reus VI, Munoz RF, Hartz DT, Maude-Griffin R. Psychological intervention and antidepressant treatment in smoking cessation. Arch Gen Psychiatry 2002; 59 (10) 930-6.
34 Haney M, Ward AS, Comer SD, Hart CL, Foltin RW, Fischman MW. Bupropion SR worsens mood during marijuana withdrawal in humans. Psychopharmacology 2001; 155 (02) 171-9.
35 Hayford KE, Patten CA, Rummans TA, Schroeder DR, Offord KP, Croghan IT, Glover ED, Sachs DP, Hurt RD. Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. Br J Psychiatry 1999; 174: 173-8.
36 Jacobi F, Höfler M, Meister W, Wittchen HU. Prävalenz, Erkennungsund Verschreibungsverhalten bei depressiven Syndromen. Eine bundesdeutsche Hausarztstudie. Nervenarzt 2002; 73 (07) 651-8.
37 Jenkins R, Bebbington P, Brugha T, Farrell M, Gill B, Lewis G, Meltzer H, Petticrew M. The National Psychiatric Morbidity surveys of Great Britain – strategy and methods. Psychol Med 1997; 27 (04) 765-74.
38 Joyce PR, Mulder RT, Luty SE, McKenzie JM, Sullivan PF, Cloninger RC. Borderline personality disorder in major depression: symptomatology, temperament, character, differential drug response, and 6-month outcome. Compr Psychiatry 2003; 44 (01) 35-43.
39 Kasen S, Cohen P, Skodol AE, Johnson JG, Smailes E, Brook JS. Childhood depression and adult personality disorder: alternative pathways of continuity. Arch Gen Psychiatry 2001; 58 (03) 231-6.
40 Kendler KS, Prescott CA, Myers J, Neale MC. The structure of genetic and environmental risk factors for common psychiatric and substance use disorders in men and women. Arch Gen Psychiatry 2003; 60 (09) 929-37.
41 Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS. National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289 (23) 3095-105.
42 Kessler RC, DuPont RL, Berglund P, Wittchen HU. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry 1999; 156 (12) 1915-23.
43 Kessler RC, Keller MB, Wittchen HU. The epidemiology of generalized anxiety disorder. Psychiatr Clin North Am 2001; 24 (01) 19-39.
44 Kessler RC, Nelson CB, McGonagle KA, Liu J, Swartz M, Blazer DG. Comorbidity of DSMIII-R major depressive disorder in the general population: results from the US National Comorbidity Survey. Br J Psychiatry Suppl 1996; (30): 17-30.
45 Lecrubier Y, Üstün TB. Panic and depression: a worldwide primary care perspective. Int Clin Psychopharmacol 1998; 13 (Suppl. 04) S7-11.
46 Lecrubier Y. The influence of comorbidity on the prevalence of suicidal behaviour. Eur Psychiatry 2001; 16 (07) 395-9.
47 Lewinsohn PM, Rohde P, Seeley JR, Klein DN. Axis II psychopathology as a function of Axis I disorders in childhood and adolescence. J Am Acad Child Adolesc Psychiatry 1997; 36 (12) 1752-9.
48 Lima MS, Reisser AA, Soares BG, Farrell M. Antidepressants for cocaine dependence. Cochrane Database Syst Rev 2003; (02) CD002950.
49 Lucey JV, O’Keane V, Butcher G, Clare AW, Dinan TG. Cortisol and prolactin responses to d-fenfluramine in non-depressed patients with obsessive-compulsive disorder: a comparison with depressed and healthy controls. Br J Psychiatry 1992; 161: 517-21.
50 Maher BS, Marazita ML, Zubenko WN, Kaplan BB, Zubenko GS. Genetic segregation analysis of alcohol and other substance-use disorders in families with recurrent, early-onset major depression. Am J Drug Alcohol Abuse 2002; 28 (04) 711-31.
51 Margolin A, Kosten TR, Avants SK, Wilkins J, Ling W, Beckson M, Arndt IO, Cornish J, Ascher JA, Li SH. A multicenter trial of bupropion for cocaine dependence in methadonemaintained patients. Drug Alcohol Depend 1995; 40 (02) 125-31.
52 Marshall RD, Olfson M, Hellman F, Blanco C, Guardino M, Struening EL. Comorbidity, impairment, and suicidality in subthreshold PTSD. Am J Psychiatry 2001; 158 (09) 1467-73.
53 Martino S, Carroll K, Kostas D, Perkins J, Rounsaville B. Dual Diagnosis Motivational Interviewing: a modification of Motivational Interviewing for substance-abusing patients with psychotic disorders. J Subst Abuse Treat 2002; 23 (04) 297-308.
54 Mason BJ, Kocsis JH, Ritvo EC, Cutler RB. A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. JAMA 1996; 275 (10) 761-7.
55 McDowell DM, Levin FR, Seracini AM, Nunes EV. Venlafaxine treatment of cocaine abusers with depressive disorders. Am J Drug Alcohol Abuse 2000; 26 (01) 25-31.
56 McGrath PJ, Nunes EV, Stewart JW, Goldman D, Agosti V, Ocepek-Welikson K, Quitkin FM. Imipramine treatment of alcoholics with primary depression: A placebo-controlled clinical trial. Arch Gen Psychiatry 1996; 53 (03) 232-40.
57 Menezes PR, Johnson S, Thornicroft G, Marshall J, Prosser D, Bebbington P, Kuipers E. Drug and alcohol problems among individuals with severe mental illness in south London. Br J Psychiatry 1996; 168 (05) 612-9.
58 Merikangas KR, Gelernter CS. Comorbidity for alcoholism and depression. Psychiatr Clin North Am 1990; 13 (04) 613-32.
59 Montoya AG, Sorrentino R, Lukas SE, Price BH. Long-term neuropsychiatric consequences of »ecstasy« (MDMA): a review. Harv Rev Psychiatry 2002; 10 (04) 212-20.
60 Nisita C, Petracca A, Akiskal HS, Galli L, Gepponi I, Cassano GB. Delimitation of generalized anxiety disorder: clinical comparisons with panic and major depressive disorders. Compr Psychiatry 1990; 31 (05) 409-15.
61 Nunes EV, Quitkin FM, Donovan SJ, Deliyannides D, Ocepek-Welikson K, Koenig T, Brady R, McGrath PJ, Woody G. Imipramine treatment of opiate-dependent patients with depressive disorders. A placebo-controlled trial. Arch Gen Psychiatry 1998; 55 (02) 153-60.
62 Nurnberger Jr JI, Foroud T, Flury L, Su J, Meyer ET, Hu K, Crowe R, Edenberg H, Goate A, Bierut L, Reich T, Schuckit M, Reich W. Evidence for a locus on chromosome 1 that influences vulnerability to alcoholism and affective disorder. Am J Psychiatry 2001; 158 (05) 718-24.
63 Oakley-Browne MA, Joyce PR, Wells JE, Bushnell JA, Hornblow AR. Christchurch Psychiatric Epidemiology Study, Part II: Six month and other period prevalences of specific psychiatric disorders. Aust N Z J Psychiatry 1989; 23 (03) 327-40.
64 O’Keane V, Dinan TG. Prolactin and cortisol responses to d-fenfluramine in major depression: evidence for diminished responsivity of central serotonergic function. Am J Psychiatry 1991; 148 (08) 1009-15.
65 Oldham JM, Skodol AE, Kellman HD, Hyler SE, Doidge N, Rosnick L, Gallaher PE. Comorbidity of axis I and axis II disorders. Am J Psychiatry 1995; 152 (04) 571-8.
66 Parrott AC. Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav 2002; 71 (04) 837-44.
67 Patten CA, Rummans TA, Croghan IT, Hurt RD, Hays JT. Development of depression during placebo-controlled trials of bupropion for smoking cessation: case reports. J Clin Psychiatry 1999; 60 (07) 436-41.
68 Petersen T, Hughes M, Papakostas GI, Kant A, Fava M, Rosenbaum JF, Nierenberg AA. Treatment-resistant depression and Axis II comorbidity. Psychother Psychosom 2002; 71 (05) 26974.
69 Petty F, Kramer GL, Davis LL, Fulton M, Adinoff B. Plasma gamma-aminobutyric acid (GABA) predicts outcome in patients with alcohol dependence. Prog Neuropsychopharmacol Biol Psychiatry 1997; 21 (05) 809-16.
70 Pomerleau OF. Nicotine and the central nervous system: biobehavioral effects of cigarette smoking. Am J Med 1992; 93 (1A): 2S-7S.
71 Rihmer Z, Szadoczky E, Furedi J, Kiss K, Papp Z. Anxiety disorders comorbidity in bipolar I, bipolar II and unipolar major depression: results from a population-based study in Hungary. J Affect Disord 2001; 67 (1-3); 175-9.
72 Robins LN, Helzer JE, Weissman MM, Orvaschel H, Gruenberg E, Burke Jr JD, Regier DA. Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry 1984; 41 (10) 949-58.
73 Robins LN, Wing J, Wittchen HU, Helzer JE, Babor TF, Burke J, Farmer A, Jablenski A, Pickens R, Regier DA. The Composite International Diagnostic Interview. An epidemiologic Instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Arch Gen Psychiatry 1988; 45 (12) 1069-77.
74 Rogers JH, Widiger TA, Krupp A. Aspects of depression associated with borderline personality disorder. Am J Psychiatry 1995; 152 (02) 268-70.
75 Ronningstam E. Pathological narcissism and narcissistic personality disorder in Axis I disorders. Harv Rev Psychiatry 1996; 03 (06) 326-40.
76 Rothschild L, Zimmerman M. Borderline personality disorder and age of onset in major depression. J Personal Disord 2002; 16 (02) 189-99.
77 Rounsaville BJ, Anton SF, Carroll K, Budde D, Prusoff BA, Gawin F. Psychiatric diagnoses of treatment-seeking cocaine abusers. Arch Gen Psychiatry 1991; 48 (01) 43-51.
78 Roy A, DeJong J, Lamparski D, George T, Linnoila M. Depression among alcoholics. Relationship to clinical and cerebrospinal fluid variables. Arch Gen Psychiatry 1991; 48 (05) 428-32.
79 Roy-Byrne PP, Pages KP, Russo JE, Jaffe C, Blume AW, Kingsley E, Cowley DS, Ries RK. Nefazodone treatment of major depression in alcohol-dependent patients: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 2000; 20 (02) 129-36.
80 Russell JM, Kornstein SG, Shea MT, McCullough JP, Harrison WM, Hirschfeld RM, Keller MB. Chronic depression and comorbid personality disorders: response to sertraline versus imipramine. J Clin Psychiatry 2003; 64 (05) 554-61.
81 Salloum IM, Cornelius JR, Thase ME, Daley DC, Kirisci L, Spotts C. Naltrexone utility in depressed alcoholics. Psychopharmacol Bull 1998; 34 (01) 111-5.
82 Sato T, Sakado K, Uehara T, Narita T, Hirano S. Personality disorder comorbidity in early-onset versus late-onset major depression in Japan. J Nerv Ment Dis 1999; 187 (04) 237-42.
83 Schmitz JM, Averill P, Stotts AL, Moeller FG, Rhoades HM, Grabowski J. Fluoxetine treatment of cocaine-dependent patients with major depressive disorder. Drug Alcohol Depend 2001; 63 (03) 207-14.
84 Schuckit MA, Monteiro MG. Alcoholism, anxiety and depression. Br J Addict 1988; 83 (12) 1373-80.
85 Scott J, Dickey B. Global burden of depression: the intersection of culture and medicine. Br J Psychiatry 2003; 183: 92-4.
86 Shea MT, Widiger TA, Klein MH. Comorbidity of personality disorders and depression: implications for treatment. J Consult Clin Psychol 1992; 60 (06) 857-68.
87 Southwick SM, Yehuda R, Giller EL. Psychological dimensions of depression in borderline personality disorder. Am J Psychiatry 1995; 152 (05) 789-91.
88 Spijker J, de Graaf R, Bijl RV, Beekman AT, Ormel J, Nolen WA. Duration of major depressive episodes in the general population: results from The Netherlands Mental Health Survey and Incidence Study (NEMESIS). Br J Psychiatry 2002; 181: 208-13.
89 Stuart S, Simons AD, Thase ME, Pilkonis P. Are personality assessments valid in acute major depression?. J Affect Disord 1992; 24 (04) 281-9.
90 Tedlow J, Smith M, Neault N, Polania L, Alpert J, Nierenberg A, Fava M. Melancholia and axis II comorbidity. Compr Psychiatry 2002; 43 (05) 331-5.
91 Teplin LA. Psychiatric and substance abuse disorders among male urban jail detainees. Am J Public Health 1994; 84 (02) 290-3.
92 Ungless MA, Whistler JL, Malenka RC, Bonci A. Single cocaine exposure in vivo induces long-term potentiation in dopamine neurons. Nature 2001; 411 (6837); 583-7.
93 Weaver T, Madden P, Charles V, Stimson G, Renton A, Tyrer P, Barnes T, Bench C, Middleton H, Wright N, Paterson S, Shanahan W, Seivewright N, Ford C. Comorbidity of Substance Misuse and Mental Illness Collaborative study team. Comorbidity of substance misuse and mental illness in community mental health and substance misuse services. Br J Psychiatry 2003; 183: 304-13.
94 Wittchen HU. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety 2002; 16 (04) 162-71.
95 Ziedonis D, Brady K. Dual diagnosis in primary care. Detecting and treating both the addiction and mental illness. Med Clin North Am 1997; 81 (04) 1017-36.
96 Ziedonis DM, Kosten TR. Pharmacotherapy improves treatment outcome in depressed cocaine addicts. J Psychoactive Drugs 1991; 23 (04) 417-25.
97 Zimmerman M, Mattia JI. Axis I diagnostic comorbidity and borderline personality disorder. Compr Psychiatry 1999; 40 (04) 245-52.